Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, a single shot poultry vaccine

VAXXITEK® HVT + IBD provides life-long immunity against Infectious Bursal Disease and Marek's Disease. It is the first vector vaccine launched in the avian market

0
56
New Delhi: Boehringer Ingelheim India has announced the launch of its poultry vaccine VAXXITEK® HVT+IBD. An innovative recombinant vaccine, VAXXITEK® HVT+IBD is a single shot vaccine, ensuring life-long protection for all types of production chickens, namely broiler, layer and breeder.
Designed to build and strengthen a stronger immune foundation in poultry, the vaccine enables better flock health and performance. VAXXITEK® HVT+IBD protects against two major immunosuppressive diseases – IBD (Infectious Bursal Disease) and Marek’s Disease, both of which are known to cause significant losses to poultry businesses.
First launched in Brazil, VAXXITEK® HVT+IBD is now available in 100 countries worldwide. With over 130 billion birds vaccinated globally, this is the first vector vaccine launched in the avian market. As the flagship poultry product of Boehringer Ingelheim, VAXXITEK® HVT + IBD is the largest selling poultry vaccine globally in terms of revenue, contributing close to 26 percent of sales in the poultry franchise globally. In India, the poultry vaccine market accounts for around USD 120mn.
Vani Manja, Managing Director, Boehringer Ingelheim India said “With the introduction of VAXXITEK® HVT+IBD, we bring a simplified and effective solution to the Indian poultry market, while providing producers with the flexibility and expected protection against two avian diseases in one product. An innovative single-dose recombinant vaccine, VAXXITEK® HVT+IBD eliminates the need for any additional field vaccination. With our holistic solutions approach, veterinarians and poultry producers are assured of vaccination process convenience and improved performance of the flock.”